[Cognitive deterioration in Parkinson's disease].
BACKGROUND
Whether there are mental changes in Parkinson s disease (EP) or not, has been a confused and contradictory subject since the earliest studies and semiological definition of the disorder. James Parkinson himself, in his study An essay on the shaking palsy (1817), stated that in the condition he described, the sense and intellect were not damaged.


METHODS
Thanks to the development of cognitive neuropsychology, at the present time there are rather more precise concepts regarding this fascinating area of neurology. We give a summary, as schematic as possible, of theory relating to the known data. 1. The presence or absence of cognitive deterioration in EP 2. The neuropsychological characteristics of cognitive involvement in EP, cognitive defects in incipient EP and in established EP. 3. The risk factor involved in the occurrence of cognitive deterioration.


CONCLUSIONS
This knowledge should be used for better understanding of the patient s mental state at every stage of the disease, during follow up studies and for the neuro conductual therapeutic and socio familial approach in each case.
Perea-Bartolomé
M V
MV
Dpto. Psicología Básica, Psicobiología y Metodolog; Universidad de Salamanca. Facultad de Psicología, Salamanca, 37005, España. vperea@gugu.usal.es
D000223:Adaptation, Psychological; D000978:Antiparkinson Agents / Q000627:therapeutic use; D003072:Cognition Disorders / Q000188:drug therapy / Q000209:etiology* / Q000628:therapy; D003131:Combined Modality Therapy; D003704:Dementia / Q000188:drug therapy / Q000209:etiology; D003863:Depression / Q000209:etiology; D005625:Frontal Lobe / Q000503:physiopathology; D006801:Humans; D007806:Language Disorders / Q000209:etiology; D008569:Memory Disorders / Q000209:etiology; D009788:Occupational Therapy; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy / Q000523:psychology*; D010468:Perceptual Disorders / Q000209:etiology; D011618:Psychotic Disorders / Q000209:etiology; D012307:Risk Factors
D000978:Antiparkinson Agents